Please assess the completion status of the following clinical trial:

Trial Title: Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hepatocellular carcinoma diagnosis according to Barcelona Clinic Liver Cancer (BCLC) staging and European Association for Study of Liver (EASL) criteria or histologically confirmed diagnosis (biopsy).~* Patients with untreated hepatocellular carcinoma, not suitable for curative treatment and having an anti-angiogenic treatment.~* Patients with no contra-indication to sorafenib treatment~* The previous treatment with surgery, chemo-embolization, radiofrequency, or conformal radiotherapy are not contra-indications to the inclusion~* Patients agreeing to participate (signed inform consent)~Exclusion Criteria:~* Patients with contra-indication to sorafenib treatment~* MRI contra-indication: ferromagnetic material, pacemaker, intraocular foreign bodies, claustrophobia, creatinine clearance below 30 ml / min by Modification of Diet in Renal Disease (MDRD) method~* True allergy to gadobenate dimeglumine~* Patients suffering from acute renal failure or chronic severe (GFR \<30 ml/min/1, 73 m²) and patients suffering from acute renal failure (regardless of severity) due to an hepatorenal syndrome~* Pregnancy or breast-feeding~* Refusal to sign the informed consent~* Patient has already been included in another study that could interfere with the results of the study. - Patients not affiliated to either the French social security system or an European health insurance.~* All persons deprived of liberty by a judicial or administrative law, patients hospitalized without consent under Articles L. 3212-1 and L. 3213-1 which are not covered by the provisions of Article L. 1121-8

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- liver Perfusion MRI (Type: EXPERIMENTAL): liver perfusion MRI will be performed in patients to assess the early response (7 days) to antiangiogenic treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).